It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
This study investigated the efficacy of a biphasic synthetic β-tricalcium phosphate/calcium sulfate (β-TCP/CS) bone graft substitute for compatibility with vancomycin (V) in combination with tobramycin (T) or gentamicin (G) evidenced by the duration of potency and the prevention and killing efficacies of P. aeruginosa (PAO1) and S. aureus (SAP231) biofilms in in vitro assays. Antibiotic loaded β-TCP/CS beads were compared with antibiotic loaded beads formed from a well characterized synthetic calcium sulfate (CS) bone void filler. β-TCP/CS antibiotic loaded showed antimicrobial potency against PAO1 in a repeated Kirby-Bauer like zone of inhibition assay for 6 days compared to 8 days for CS. However, both bead types showed potency against SAP231 for 40 days. Both formulations loaded with V + T completely prevented biofilm formation (CFU below detection limits) for the 3 days of the experiment with daily fresh inoculum challenges (P < 0.001). In addition, both antibiotic loaded materials and antibiotic combinations significantly reduced the bioburden of pre-grown biofilms by between 3 and 5 logs (P < 0.001) with V + G performing slightly better against PAO1 than V + T. Our data, combined with previous data on osteogenesis suggest that antibiotic loaded β-TCP/CS may have potential to stimulate osteogenesis through acting as a scaffold as well as simultaneously protecting against biofilm infection. Future in vivo experiments and clinical investigations are warranted to more comprehensively evaluate the use of β-TCP/CS in the management of orthopaedic infections.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 The Ohio State University Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.412332.5) (ISNI:0000 0001 1545 0811); Southern Medical University Nanfang Hospital, Department of Orthopaedics, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
2 The Ohio State University Nationwide Children’s Hospital, Center for Clinical and Translational Research, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)
3 The Ohio State University Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.412332.5) (ISNI:0000 0001 1545 0811)
4 Biocomposites Ltd., Keele, Staffordshire, UK (GRID:grid.412332.5)
5 The Ohio State University Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.412332.5) (ISNI:0000 0001 1545 0811); The Ohio State University Wexner Medical Center, Department of Orthopaedics, Columbus, USA (GRID:grid.412332.5) (ISNI:0000 0001 1545 0811); University of Southampton, National Centre for Advanced Tribology at Southampton (nCATS) and National Biofilm Innovation Centre (NBIC), Department of Mechanical Engineering, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297)